About this trial
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.
Eligibility criteria
Qualifiers
Age12 years or older, any gender;
Signed"Informed Consent Form";
Clinically diagnosed with non-segmental vitiligo;
Vitiligo area less than 10% of body surface area;
Disqualifiers
Allergy to ruxolitinib cream;
Pregnant or lactating women;
Any condition deemed inappropriate for study participation by the investigator.
Trial design
Treatments tested in this trial
- Ruxolitinib 1.5% Cream BID